Organovo Holdings logo

Organovo HoldingsNASDAQ: ONVO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 February 2012

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A
$10.92 M
-85%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-25%vs. 3y high
70%vs. sector
100.21
-25%vs. 3y high
95%vs. sector

Price

after hours | 73 min ago
$0.76+$0.01(+1.32%)

Dividend

No data over the past 3 years
$29.00 K$30.00 K
$29.00 K-$3.04 M

Analysts recommendations

Institutional Ownership

ONVO Latest News

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
GlobeNewsWire14 May 2024 Sentiment: POSITIVE

Organovo is scheduled to share information about its primary clinical-stage medication, FXR314, at DDW2024, taking place in Washington, D.C. from May 18-21, 2024.

Organovo's fatty liver disease drug meets main goal in mid-stage study
Reuters15 April 2024 Sentiment: POSITIVE

Organovo Holdings announced on Monday that its experimental drug for a certain type of fatty liver disease achieved the primary objective in a mid-stage trial, causing its stock to rise by almost 27% in premarket trading.

Organovo to Participate in the H.C. Wainwright Global Investment Conference
GlobeNewsWire08 September 2023 Sentiment: POSITIVE

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

What type of business is Organovo Holdings?

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

What sector is Organovo Holdings in?

Organovo Holdings is in the Healthcare sector

What industry is Organovo Holdings in?

Organovo Holdings is in the Biotechnology industry

What country is Organovo Holdings from?

Organovo Holdings is headquartered in United States

When did Organovo Holdings go public?

Organovo Holdings initial public offering (IPO) was on 14 February 2012

What is Organovo Holdings website?

https://www.organovo.com

Is Organovo Holdings in the S&P 500?

No, Organovo Holdings is not included in the S&P 500 index

Is Organovo Holdings in the NASDAQ 100?

No, Organovo Holdings is not included in the NASDAQ 100 index

Is Organovo Holdings in the Dow Jones?

No, Organovo Holdings is not included in the Dow Jones index

When does Organovo Holdings report earnings?

The next expected earnings date for Organovo Holdings is 09 August 2024